A study about immunogenicity and safety of Phase 3 and 4 immunization with combined measles-rubella vaccine

A study about immunogenicity and safety of Phase 3 and 4 immunization with combined measles-rubella vaccine - A study about immunogenicity and safety of Phase 3 and 4 immunization with MR vaccine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011832

Enrollment

Registered

2013-09-23

Start date

2008-02-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

measles and rubella

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy children or adolescents with an agreement of a guardian on this study, who received Phase 3 or Phase 4 MR immunization at the pediatric outpatient clinic of Konan Kosei Hospital in Japan, from Feb 2008 to Oct 2012.

Exclusion criteria

Exclusion criteria: We exclude the subjects from whom we could not obtain the paired serum samples (before and 4-6 weeks after the immunization).

Design outcomes

Primary

Measure	Time frame
1) Measles HI and NT antibody positive rates and mean titers before and 4-6 weeks after Phase 3 and Phase 4 MR immunization, and rubella HI antibody positive rates and mean titers before and 4-6 weeks after the both immunization. 2) Before and after the both MR immunization, comparison of the antibody positive rates and the mean antibody titers. 3) Incidence of clinical reactions for 4 weeks after the both MR immunization. 4) Morbidity of measles and rubella after the both immunization.	—

Measure

Time frame

1) Measles HI and NT antibody positive rates and mean titers before and 4-6 weeks after Phase 3 and Phase 4 MR immunization, and rubella HI antibody positive rates and mean titers before and 4-6 weeks after the both immunization. 2) Before and after the both MR immunization, comparison of the antibody positive rates and the mean antibody titers. 3) Incidence of clinical reactions for 4 weeks after the both MR immunization. 4) Morbidity of measles and rubella after the both immunization.

—

Countries

Japan

Contacts

Public ContactNaoko Nishimura

Konan Kosei Hospital Department of Pediatrics

naon@konan.jaaikosei.or.jp0587-51-3333

Outcome results